Clinical Laserthermia Systems AB OMXSTO:CLS_B:
Q3 REVENUE AMOUNTED TO SEK 2.8 MILLION
Q3 OPERATING LOSS SEK 7.42 MILLION
Clinical Laserthermia Systems Q3 Revenue SEK 2.8 Mln
Clinical Laserthermia Systems AB on 6ix
Earlier from Clinical Laserthermia Systems
- CLS-sponsored neuro LITT study in patients with malignant brain tumor shows positive results
- Clinical Laserthermia Systems AB: Quarterly Trading Report 2025 Q3
- CLS Raises SEK 20.9 Mln Through Full Subscription Of Warrants
- CLS_B: Record Q2 sales and improved margins drive narrowed losses and strong growth outlook
- CLS_B: Revenue up 43% and operating loss halved as CLS accelerates neurosurgery commercialization
Later from Clinical Laserthermia Systems
- CLS Initiates Recruitment Process For Permanent Chief Financial Officer
- Clinical Laserthermia Systems Says Continues To Maintain Targets For 2026
- CLS Receives Order Worth SEK 23 Mln For Prism Business
- Sweden's CLS Q1 sales fall 72% after partner talks
- CLS Enters Research Agreement With U.S. National Cancer Institute
Follow Clinical Laserthermia Systems into a list and get an email when it puts out news.
Follow Clinical Laserthermia Systems